Predicting survival in patients with hepatocellular carcinoma: A UK perspective

Unfolded protein response activation contributes to chemoresistance in hepatocellular carcinoma

“…UPR activation may contribute to HCC chemoresistance. Eur J Gastroenterol Introduction Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide with 626 000 cases per year [1] and the incidence is rising. In the UK the incidence has risen from 2.5 to 3.9 per 100 000 of the population between 1993 and 2005 [2].…”

Quantitative Analysis of Circulating Methylated DNA as a Biomarker for Hepatocellular Carcinoma

“…In China, where chronic infection with hepatitis B virus (HBV) is prevalent, the incidence of HCC is Ͼ30 cases per 100 000 population (3,4 ). Despite numerous advances in the treatment of HCC during the last decade, the 5-year survival rate remains Ͻ40% (5,6 ), and late presentation remains an important obstacle to successful treatment. In fact, many HCC patients have already developed locally advanced disease or distant metastasis by the time of presentation (5,6 ).…”

“…Despite numerous advances in the treatment of HCC during the last decade, the 5-year survival rate remains Ͻ40% (5,6 ), and late presentation remains an important obstacle to successful treatment. In fact, many HCC patients have already developed locally advanced disease or distant metastasis by the time of presentation (5,6 ). In this regard, biomarkers have been developed for early HCC detection (7 ), with ␣-fetoprotein (AFP) being the most widely used clinically.…”

Artificial Neural Network Model for Predicting 5-year Mortality after Surgery for Hepatocellular Carcinoma and Performance Comparison with Logistic Regression Model: A Nationwide Taiwan Database Study

“…Although substantially improved outcome prediction models have been developed for many surgical procedures in recent years, studies of HCC outcome prediction models have had major shortcomings [11,12]. For example, few have used longitudinal data for more than two years.…”